BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Hemispherx preclinical data

In an insulin-like growth factor binding protein 2 ( IGFBP2) transgenic mouse model of breast cancer, IGFBP2 antigens plus adjuvant Ampligen significantly inhibited tumor growth by 60% vs. 23%...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >